Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Overview of attention for article published in Investigational New Drugs, February 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 13,072 followers.

むむ〜オシメルチニブがある以上なかなか厳しい領域ですね…同じP1だし、ヤンセンのEGFR-cMET抗体とかと併用で開発してみてほしい。シナジー効果が出れば面白いかも。

《短報》【T790M陽性肺がん】第3世代EGFR-TKI「TAS-121」治療による奏効率28％。T790M陰性例では19％に奏効。〔Invest New Drugs〕 https://t.co/eeCujqbh9T https://t.co/eeCujqbh9T